anti-ageing activity of the Hermecos Age Defense Contour Cream

A single arm clinical study to evaluate the anti-ageing activity of the Hermecos Age Defense Contour Cream - NIL

Status

Active, not recruiting

Phases

Phase 4

Study type

Observational

Source

CTRI

Registry ID

CTRI/2025/10/095979

Enrollment

Registered

2025-10-13

Start date

Unknown

Completion date

Unknown

Last updated

2025-11-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Interventions

Intervention1: Test Product: Hermecos Age Defense Contour Cream: Dose: Gently use approx. 0.5 to 1gm of the Hermecos Age Defense Contour Cream on the face twice a day for 4 weeks. Route of Administra

Eligibility

Inclusion criteria

Inclusion criteria: 1) Gender: Male or Female with age 18-55 2) Subjects with mild noticeable wrikles 3) Subjects willing to give written informed consent 4) Women of child bearing potential must have a negative urine pregnancy test prior to study entry. 5) Are free of any systemic or dermatologic disorder, which, in the opinion of the investigator, will interfere with the study results or increase the risk of adverse events. 6) Are willing to avoid prolonged exposure of the treatment area to ultraviolet radiation (natural or artificial) for the duration of the study.

Exclusion criteria

Exclusion criteria: 1. Subjects who are pregnant, breast-feeding, or planning to become pregnant during the study. 2. Have any evidence of systemic cancer, squamous cell carcinoma, basal cell carcinoma, in the last 5 years, or any other confounding skin condition. 3. Have open sores or open lesions in the treatment area(s). 4. Have any condition that, in the opinion of the investigator, would confound the safety and/or efficacy assessments of the product. 5. Have participated in any interventional clinical trial in the previous 90 days. 6. Have a known sensitivity to any of the constituents of the test product including sensitivities to (mention some of active ingredient’s name) 7. Have used, are using, or are planning to use immunosuppressive or immunomodulatory medication (i.e., biologics), including corticosteroids. 8. Have not skin related issues.

Design outcomes

Primary

Measure	Time frame
1. change in Skin Gloss 2. change in Skin Pigmentation 3. change in skin firmness 4. change in skin hydration 5. dark spots 6. wrinkles 7. Change in TEWL 8. Visioscan 9. HD imagingTimepoint: At T0min, 14days, 28days	—

Secondary

Measure	Time frame
Not ApplicableTimepoint: Not Applicable	—

Countries

India

Contacts

Public ContactPuneet Mittal

CCFT Laboratories

puneetmittal@mgcts.org08937015757

Outcome results